Literature DB >> 25862843

Comparative characterization of stem cell marker expression, metabolic activity and resistance to doxorubicin in adherent and spheroid cells derived from the canine prostate adenocarcinoma cell line CT1258.

Wen Liu1, Mohammed Moulay2, Saskia Willenbrock2, Catrin Roolf3, Christian Junghanss3, Anaclet Ngenazahayo4, Ingo Nolte5, Hugo Murua Escobar1.   

Abstract

BACKGROUND: Canine prostate cancer represents a spontaneous animal model for the human counterpart. Cells with stem cell-like character are considered to play a major role in therapeutic resistance and tumor relapse. Thus, the identification of markers allowing for recognition and characterization of these cells is essential.
MATERIALS AND METHODS: Expression of 12 stem cell marker genes in the canine prostate cancer cell line CT1258 and spheroid cells generated from these was analyzed by quantitative real-time PCR. In CT1258 and the generated spheroid cells, CD44 and CD133 expression was analyzed by flow cytometry, as well as proliferation and doxorubicin resistance.
RESULTS: Integrin alpha-6 (ITGA6) expression and metabolic activity were significantly up-regulated in CT1258-derived spheroid cells, while doxorubicin resistance remained comparable.
CONCLUSION: ITGA6 de-regulation and metabolic activity appear to be characteristic of the generated spheres, indicating potential intervention targets. Copyright
© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Prostate cancer; cancer stem cell marker; canine cancer stem cells; spheroid cell clusters

Mesh:

Substances:

Year:  2015        PMID: 25862843

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

1.  Monoclonal Antibodies 13A4 and AC133 Do Not Recognize the Canine Ortholog of Mouse and Human Stem Cell Antigen Prominin-1 (CD133).

Authors:  Kristina Thamm; Sylvi Graupner; Carsten Werner; Wieland B Huttner; Denis Corbeil
Journal:  PLoS One       Date:  2016-10-04       Impact factor: 3.240

2.  Characterization of six canine prostate adenocarcinoma and three transitional cell carcinoma cell lines derived from primary tumor tissues as well as metastasis.

Authors:  Eva-Maria Packeiser; Marion Hewicker-Trautwein; Heike Thiemeyer; Annika Mohr; Johannes Junginger; Jan Torben Schille; Hugo Murua Escobar; Ingo Nolte
Journal:  PLoS One       Date:  2020-03-13       Impact factor: 3.240

3.  Establishment and characterization of stable red, far-red (fR) and near infra-red (NIR) transfected canine prostate cancer cell lines.

Authors:  Wen Liu; Sina Sender; Weibo Kong; Julia Beck; Anett Sekora; Kirsten Bornemann-Kolatzki; Ekkehart Schuetz; Christian Junghanss; Bertram Brenig; Ingo Nolte; Hugo Murua Escobar
Journal:  Cancer Cell Int       Date:  2020-04-29       Impact factor: 5.722

4.  Isoquinolinamine FX-9 Exhibits Anti-Mitotic Activity in Human and Canine Prostate Carcinoma Cell Lines.

Authors:  Jan Torben Schille; Ingo Nolte; Eva-Maria Packeiser; Laura Wiesner; Jens Ingo Hein; Franziska Weiner; Xiao-Feng Wu; Matthias Beller; Christian Junghanss; Hugo Murua Escobar
Journal:  Int J Mol Sci       Date:  2019-11-07       Impact factor: 5.923

5.  PDA Indolylmaleimides Induce Anti-Tumor Effects in Prostate Carcinoma Cell Lines Through Mitotic Death.

Authors:  Jan Torben Schille; Ingo Nolte; Julia Beck; Daria Jilani; Catrin Roolf; Anahit Pews-Davtyan; Arndt Rolfs; Larissa Henze; Matthias Beller; Bertram Brenig; Christian Junghanss; Ekkehard Schütz; Hugo Murua Escobar
Journal:  Front Vet Sci       Date:  2021-01-20

6.  RNA-seq of nine canine prostate cancer cell lines reveals diverse therapeutic target signatures.

Authors:  Hugo Murua Escobar; Ingo Nolte; Eva-Maria Packeiser; Leila Taher; Weibo Kong; Mathias Ernst; Julia Beck; Marion Hewicker-Trautwein; Bertram Brenig; Ekkehard Schütz
Journal:  Cancer Cell Int       Date:  2022-02-02       Impact factor: 5.722

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.